# US 2021/0260161 A1 · Fgf-21 formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260161 A1
- Document ID: US20210260161A1
- Status: Published application
- Kind: A1
- Application number: 17/257,530
- Filed: 2019-07-02
- Published: 2021-08-26
- Earliest claimed: 2018-07-03
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Thomas PALM; Mehrnaz KHOSSRAVI; Sanket PATKE
- Web page: https://patentgrep.com/patent/US20210260161A1

## CPC

- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present application provides pharmaceutical formulations comprising a FGF-21 polypeptide, e.g., a modified FGF-21 polypeptide such as PEG-FGF-21, and one or more stabilizers such as the chelator DPTA. The formulations can be can further stabilized by including a surfactant such as polysorbate 80 and/or adjusting the pH to about 7.1. Also provided are methods of manufacture, methods of treatment, and kits.

## Claims

### Claim 1

A pharmaceutical formulation comprising a fibroblast growth factor 21 (FGF-21) polypeptide and an aminopolycarboxylic acid cation chelator, wherein the formulation has improved stability compared to a reference formulation that does not contain the aminopolycarboxylic acid cation chelator.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, which exhibits one or more of:
(a) a lower rate of polypeptide deamidation when stored at 40° C. for about a month with respect to the reference formulation;
(b) a lower rate of high molecular weight (HMW) polypeptide aggregation when stored at 40° C. for about a month with respect to the reference formulation; or
(c) both (a) and (b).

### Claim 3 (depends on 1, 2)

The pharmaceutical formulation of claim 1 or 2, wherein the aminopolycarboxylic acid cation chelator mitigates oxidation of one or more methionines corresponding to amino acid 1 and/or amino acid 169 of SEQ ID NO: 1 at 25° C. and/or 40° C.

### Claim 4 (depends on 1, 2)

The pharmaceutical formulation of claim 1 or 2, wherein the aminopolycarboxylic acid cation chelator is diethylenetriaminepentaacetic acid (DTPA).

### Claim 5 (depends on 4)

The pharmaceutical formulation of claim 4, wherein the DTPA cation chelator is present in an amount between about 10 μM and about 100 μM DTPA, between about 20 μM and about 90 μM DTPA, between about 30 μM and about 80 μM DTPA, between about 25 μM and about 75 μM DTPA, or between about 40 μM and about 60 μM DTPA, or between about 30 μM and about 70 μM DTPA, or between about 40 μM and about 70 μM DTPA.

### Claim 6 (depends on 4, 5)

The pharmaceutical formulation of claim 4 or 5, wherein the DTPA cation chelator is present in an amount of about 40 μM, about 45 μM, about 50 μM, about 55 μM, or about 60 μM DTPA.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The pharmaceutical formulation of any one of claims 1 to 6, wherein the pH is above 6.5, above 6.6, above 6.7, above 6.8, above 6.9, above 7.0, above 7.1, above 7.2, above 7.3, above 7.4, or above 7.5.

### Claim 8 (depends on 7)

The pharmaceutical formulation of claim 7, wherein the pH is between about 6.7 and about 7.5, about 6.8 and about 7.5, about 6.9 and about 7.4, about 7.0 and about 7.3, about 7.1 and 7.2, about 7.1 and about 7.3, about 7.1 and about 7.4, or about 7.1 and about 7.5.

### Claim 9 (depends on 7)

The pharmaceutical formulation of claim 7, wherein the pH is about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, or about 7.5.

### Claim 10 (depends on 7, 8, 9)

The pharmaceutical formulation of any one of claims 7 to 9, wherein the pharmaceutical formulation is more stable than a reference formulation with a pH of 6.5.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The pharmaceutical formulation of any one of claims 1 to 10, further comprising a surfactant.

### Claim 12 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the surfactant is a nonionic surfactant.

### Claim 13 (depends on 12)

The pharmaceutical formulation of claim 12, wherein the nonanionic surfactant is a polysorbate.

### Claim 14 (depends on 13)

The pharmaceutical formulation of claim 13, wherein the polysorbate is polyoxyethylene (20) sorbitan monooleate (polysorbate 80).

### Claim 15 (depends on 14)

The pharmaceutical formulation of claim 14, wherein the polysorbate 80 surfactant is present in an amount of about 0.01% to about 0.1% (w/v), about 0.02% to about 0.09% (w/v), about 0.03% to about 0.08% (w/v), about 0.04% to about 0.07% (w/v), or about 0.05% to about 0.06% (w/v).

### Claim 16 (depends on 14, 15)

The pharmaceutical formulation of claim 14 or 15, wherein the polysorbate 80 surfactant is present in an amount of at least about 0.01% (w/v), at least about 0.02% (w/v), at least about 0.03% (w/v), at least about 0.04% (w/v), at least about 0.05% (w/v), at least about 0.06% (w/v), at least about 0.07% (w/v), at least about 0.08% (w/v), at least about 0.09% (w/v) or at least about 0.1% (w/v).

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The pharmaceutical formulation of any one of claims 11 to 16, wherein the surfactant mitigates particulate and/or air bubble formation when agitated on a shaker.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The pharmaceutical formulation of any one of claims 1 to 17, further comprising an amino acid buffering agent.

### Claim 19 (depends on 18)

The pharmaceutical formulation of claim 18, wherein the amino acid buffering agent is histidine.

### Claim 20 (depends on 19)

The pharmaceutical formulation of claim 19, wherein the histidine buffering agent is present in an amount of about 10 mM to about 100 mM histidine, about 20 mM to about 90 mM histidine, about 30 mM to about 80 mM histidine, about 40 mM to about 70 mM histidine, about 10 mM to about 30 mM histidine, about 15 mM to about 25 mM histidine, about 17.5 to about 22.5 histidine, or about 40 mM to about 60 mM histidine.

### Claim 21 (depends on 19, 20)

The pharmaceutical formulation of claim 19 or 20, wherein the histidine buffering agent is present in an amount of about 10 mM histidine, about 15 mM histidine, about 20 mM histidine, about 25 mM histidine, about 30 mM histidine, about 35 mM histidine, about 40 mM histidine, about 45 mM histidine or about 50 mM histidine.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The pharmaceutical formulation of any one of claims 1 to 21, further comprising an osmotic regulator.

### Claim 23 (depends on 22)

The pharmaceutical formulation of claim 22, wherein the osmotic regulator comprises a sugar.

### Claim 24 (depends on 23)

The pharmaceutical formulation of claim 23, wherein the sugar is sucrose.

### Claim 25 (depends on 24)

The pharmaceutical formulation of claim 24, wherein the sucrose osmotic regulator is present in an amount of about 100 mM to about 1 M sucrose, about 200 mM to about 900 mM, about 300 mM to about 800 mM, about 400 mM to about 700 mM, or about 500 mM to about 600 mM.

### Claim 26 (depends on 24, 25)

The pharmaceutical formulation of claim 24 or 25, wherein the sucrose osmotic regulator is present in an amount of about 100 mM sucrose, about 200 mM sucrose, about 300 mM sucrose, about 400 mM sucrose, about 500 mM sucrose, about 600 mM sucrose, about 700 mM sucrose, about 800 mM sucrose, about 900 mM sucrose, or about 1M sucrose.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The pharmaceutical formulation of any one of claims 1 to 26, wherein the FGF-21 polypeptide is a modified FGF-21 polypeptide.

### Claim 28 (depends on 27)

The pharmaceutical formulation of claim 27, wherein the modified FGF-21 polypeptide comprises a polypeptide having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 3, wherein the polypeptide has a FGF-21 activity.

### Claim 29 (depends on 27, 28)

The pharmaceutical formulation of claim 27 or 28, wherein the modified FGF-21 polypeptide is linked to a half-life extending moiety.

### Claim 30 (depends on 29)

The pharmaceutical formulation of claim 29, wherein the modified FGF-21 polypeptide is linked to the half-life extending moiety via the side chain of a non-naturally encoded amino in the sequence of the FGF-21 polypeptide.

### Claim 31 (depends on 29, 30)

The pharmaceutical formulation of claim 29 or 30, wherein the half-life extending moiety comprises albumin, an immunoglobulin constant region or a portion thereof, an immunoglobulin-binding polypeptide, an immunoglobulin G (IgG), albumin-binding polypeptide (ABP), a PASylation moiety, a HESylation moiety, XTEN, an Fc region, and any combination thereof.

### Claim 32 (depends on 29, 30)

The pharmaceutical formulation of claim 29 or 30, wherein the half-life extending moiety comprises a water soluble polymer.

### Claim 33 (depends on 32)

The pharmaceutical formulation of claim 32, wherein the water soluble polymer is a polyethylene glycol (PEG).

### Claim 34 (depends on 33)

The pharmaceutical formulation of claim 33, wherein the PEG has an average molecular weight between about 10 kDa and about 40 kDa.

### Claim 35 (depends on 33, 34)

The pharmaceutical formulation of claim 33 or 34, wherein the PEG has an average molecular weight of about 30 kDa.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The pharmaceutical formulation of any one of claims 30 to 35, wherein the non-naturally encoded amino acid is a phenylalanine derivative.

### Claim 37 (depends on 36)

The pharmaceutical formulation of claim 36, wherein the phenylalanine derivative is para-acetyl-L-phenylalanine.

### Claim 38 (depends on 36, 37)

The pharmaceutical formulation of claim 36 or 37, wherein the half-life extending moiety is linked to the non-naturally encoded amino acid via an oxime linkage.

### Claim 39 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38)

The pharmaceutical formulation of any one of claims 30 to 38, wherein the non-naturally encoded amino acid replaces amino acid Glutamine 109 of SEQ ID NO: 3.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The pharmaceutical formulation of any one of claims 1 to 39, wherein the FGF-21 polypeptide is present at a concentration between about 1 mg/ml and about 40 mg/ml.

### Claim 41 (depends on 40)

The pharmaceutical formulation of claim 40, wherein the FGF-21 polypeptide is present at a concentration of about 10 mg/ml or about 20 mg/ml.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The pharmaceutical formulation of any one of claims 1 to 41, wherein the FGF-21 polypeptide is present in an amount between about 1 mg and about 40 mg per dose.

### Claim 43 (depends on 42)

The pharmaceutical formulation of claim 42, wherein the FGF-21 polypeptide is present in an amount of about 1 mg per dose, about 5 mg per dose, about 10 mg per dose, about 20 mg per dose, or about 40 mg per dose.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The pharmaceutical formulation of any one claims 1 to 43, wherein the formulation is formulated for subcutaneous administration.

### Claim 45 (depends on 44)

The pharmaceutical formulation of claim 44, wherein the formulation is formulated for subcutaneous administration with a safety syringe.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The pharmaceutical formulation of any one of claims 1 to 45, wherein the formulation is formulated for daily or weekly administration.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The pharmaceutical formulation of any one of claims 1 to 46, wherein the formulation is an aqueous formulation.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The pharmaceutical formulation of any one of claims 1 to 47, wherein the FGF-21 polypeptide is a PEG-FGF-21 (SEQ ID NO: 2).

### Claim 49

A pharmaceutical formulation comprising:
(i) a FGF-21 polypeptide;
(ii) histidine at a concentration between about 10 mM and about 50 mM;
(iii) sucrose at a concentration between about 100 mM and about 1M;
(iv) Polysorbate 80 at a concentration between about 0.01% and about 0.1% (w/v); and,
(v) DTPA at a concentration between about 10 μM and about 100 μM;
wherein the pH of the formulation is between about 6.7 and about 7.5.

### Claim 50

A pharmaceutical formulation comprising:
(i) a FGF-21 polypeptide;
(ii) histidine at a concentration of about 20 mM;
(iii) sucrose at a concentration of about 600 mM;
(iv) Polysorbate 80 at a concentration of about 0.05% (w/v); and
(v) DTPA at a concentration of about 50 μM;
wherein the pH is about 7.1.

### Claim 51

A pharmaceutical formulation comprising:
(i) a FGF-21 polypeptide;
(ii) histidine at a concentration of 20 mM;
(iii) sucrose at a concentration of 600 mM;
(iv) Polysorbate 80 at a concentration of 0.05% (w/v); and
(v) DTPA at a concentration of 50 μM;
wherein the pH is 7.1.

### Claim 52

A pharmaceutical formulation comprising:
(i) a FGF-21 polypeptide;
(ii) histidine at a concentration of about 20 mM; and
(iii) sucrose at a concentration of about 600 mM;
wherein the pH is about 7.0.

### Claim 53

A pharmaceutical formulation comprising:
(i) a FGF-21 polypeptide;
(ii) histidine at a concentration of 20 mM; and
(iii) sucrose at a concentration of 600 mM;
wherein the pH is 7.0.

### Claim 54

A pharmaceutical formulation comprising:
(i) PEG-FGF-21 at a concentration of about 10 mg/mL;
(ii) histidine at a concentration of about 20 mM;
(iii) sucrose at a concentration of about 600 mM;
(iv) Polysorbate 80 at a concentration of about 0.05% (w/v); and
(v) DTPA at a concentration of about 50 μM;
wherein the pH is about 7.1.

### Claim 55

A pharmaceutical formulation comprising:
(i) PEG-FGF-21 at a concentration of about 20 mg/mL;
(ii) histidine at a concentration of about 20 mM;
(iii) sucrose at a concentration of about 600 mM;
(iv) Polysorbate 80 at a concentration of about 0.05% (w/v); and
(v) DTPA at a concentration of about 50 μM;
wherein the pH is about 7.1.

### Claim 56

A pharmaceutical formulation comprising:
(i) PEG-FGF-21 at a concentration of 10 mg/mL;
(ii) histidine at a concentration of 20 mM;
(iii) sucrose at a concentration of 600 mM;
(iv) Polysorbate 80 at a concentration of 0.05% (w/v); and
(v) DTPA at a concentration of 50 μM;
wherein the pH is 7.1.

### Claim 57

A pharmaceutical formulation comprising:
(i) PEG-FGF21 at a concentration of 20 mg/mL;
(ii) histidine at a concentration of 20 mM;
(iii) sucrose at a concentration of 600 mM;
(iv) Polysorbate 80 at a concentration of 0.05% (w/v); and
(v) DTPA at a concentration of 50 μM;
wherein the pH is 7.1.

### Claim 58

A method to improve the stability of a pharmaceutical formulation comprising a FGF-21 polypeptide comprising admixing an aminopolycarboxylic acid cation chelator, wherein the formulation has improved stability compared to a reference formulation that does not contain the aminopolycarboxylic acid cation chelator.

### Claim 59 (depends on 58)

The method of claim 58, wherein the improvement in stability comprises (i) an increase in polypeptide physical stability, (ii) an increase in polypeptide chemical stability, or (iii) a combination thereof.

### Claim 60 (depends on 59)

The method of claim 59, wherein the increase in physical stability comprises (i) prevention or decrease of polypeptide aggregation, (ii) prevention or decrease of polypeptide fragmentation, or (iii) a combination thereof.

### Claim 61 (depends on 60)

The method of claim 60, wherein the increase in chemical stability comprises (i) prevention or decrease of polypeptide deamidation, (ii) prevention or decrease of polypeptide oxidation, or (iii) a combination thereof.

### Claim 62 (depends on 58, 59, 60, 61)

The method of any one of claims 58 to 61, wherein the improvement in stability comprises one or more of:
(a) a lower rate of polypeptide deamidation when stored at 40° C. for about a month with respect to the reference formulation;
(b) a lower rate of high molecular weight (HMW) polypeptide aggregation when stored at 40° C. for about a month with respect to the reference formulation; or
(c) both (a) and (b).

### Claim 63 (depends on 58, 59, 60, 61, 62)

The method of any one of claims 58 to 62, wherein the aminopolycarboxylic acid cation chelator mitigates oxidation of one or more methionines corresponding to amino acid 1 and/or amino acid 169 of SEQ ID NO: 3 at 25° C. and/or 40° C.

### Claim 64 (depends on 58, 59, 60, 61, 62, 63)

The method of any one of claims 58 to 63, wherein the aminopolycarboxylic acid cation chelator is DTPA.

### Claim 65 (depends on 64)

The method of claim 64, wherein the DTPA cation chelator is present in an amount between about 10 μM and about 100 μM DTPA, between about 20 μM and about 90 μM DTPA, between about 25 μM and about 75 μM DTPA, between about 40 μM and about 60 μM DTPA, between about 30 μM and about 70 μM DTPA, between about 30 μM and about 80 μM DTPA, or between about 40 μM and about 70 μM.

### Claim 66 (depends on 64, 65)

The method of claim 64 or 65, wherein the DTPA cation chelator is present in an amount of about 40 μM, about 45 μM, about 50 μM, about 55 μM, or about 60 μM DTPA.

### Claim 67 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 58 to 66, further comprising adjusting the pH to above 6.5, above 6.6, above 6.7, above 6.8, above 6.9, or above 7.0.

### Claim 68 (depends on 67)

The method of claim 67, wherein the pH is adjusted to between about 6.8 and about 7.5, or between about 6.9 and about 7.4, or between about 7.0 and about 7.3, or between about 7.1 and 7.2, or between about 7.1 and about 7.3, or between about 7.1 and about 7.4, or between about 7.1 and about 7.5.

### Claim 69 (depends on 67)

The method of claim 67, wherein the adjusted pH is about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, or about 7.5.

### Claim 70 (depends on 67, 68, 69)

The method of any one of claims 67 to 69, wherein the formulation is more stable than the reference formulation having a pH of 6.5.

### Claim 71 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 58 to 70, further comprising admixing a surfactant.

### Claim 72 (depends on 71)

The method of claim 71, wherein the surfactant is a nonionic surfactant.

### Claim 73 (depends on 72)

The method of claim 72, wherein the nonanionic surfactant is a polysorbate.

### Claim 74 (depends on 73)

The method of claim 73, wherein the polysorbate is polysorbate 80.

### Claim 75 (depends on 74)

The method of claim 74, wherein the polysorbate 80 surfactant is admixed in an amount of about 0.01% to about 0.1% (w/v), about 0.02% to about 0.09% (w/v), about 0.03% to about 0.08% (w/v), about 0.04% to about 0.07% (w/v), or about 0.05% to about 0.06% (w/v).

### Claim 76 (depends on 74, 75)

The method of claim 74 or 75, wherein polysorbate 80 surfactant is admixed in an amount of at least about 0.01% (w/v), at least about 0.02% (w/v), at least about 0.03% (w/v), at least about 0.04% (w/v), at least about 0.05% (w/v), at least about 0.06% (w/v), at least about 0.07% (w/v), at least about 0.08% (w/v), at least about 0.09% (w/v) or at least about 0.1% (w/v).

### Claim 77 (depends on 71, 72, 73, 74, 75, 76)

The method of any one of claims 71 to 76, wherein the surfactant mitigates particulate formation and/or air bubble formation when agitated on a shaker.

### Claim 78 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 58 to 77, further comprising admixing an amino acid buffering agent.

### Claim 79 (depends on 78)

The method of claim 78, wherein the amino acid buffering agent is histidine.

### Claim 80 (depends on 79)

The method of claim 79, wherein the histidine buffering agent is admixed in an amount of about 10 mM to about 100 mM histidine, about 20 mM to about 90 mM histidine, about 30 mM to about 80 mM histidine, about 40 mM to about 70 mM histidine, about 10 mM to about 30 mM histidine, about 15 mM to about 25 mM histidine, about 17.5 mM to about 22.5 mM histidine, or about 40 mM to about 60 mM histidine.

### Claim 81 (depends on 79, 80)

The method of claim 79 or 80, wherein the histidine buffering agent is admixed in an amount of about 10 mM histidine, about 15 mM histidine, about 20 mM histidine, about 25 mM histidine, about 30 mM histidine, about 35 mM histidine, about 40 mM histidine, about 45 mM histidine or about 50 mM histidine.

### Claim 82 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 58 to 81, further comprising admixing an osmotic regulator.

### Claim 83 (depends on 82)

The method of claim 82, wherein the osmotic regulator comprises a sugar.

### Claim 84 (depends on 83)

The method of claim 83, wherein the sugar is sucrose.

### Claim 85 (depends on 84)

The method of claim 84, wherein the sucrose osmotic regulator is admixed in an amount of about 100 mM to about 1 M sucrose, about 200 mM to about 900 mM sucrose, about 300 mM to about 800 mM sucrose, about 400 mM to about 700 mM sucrose, or about 500 mM to about 600 mM sucrose.

### Claim 86 (depends on 84, 85)

The method of claim 84 or 85, wherein the sucrose osmotic regulator is admixed in an amount of about 100 mM sucrose, about 200 mM sucrose, about 300 mM sucrose, about 400 mM sucrose, about 500 mM sucrose, about 600 mM sucrose, about 700 mM sucrose, about 800 mM sucrose, about 900 mM sucrose, or about 1M sucrose.

### Claim 87 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method of one of claims 58 to 86, wherein the FGF-21 polypeptide is a modified FGF-21 polypeptide.

### Claim 88 (depends on 87)

The method of claim 87, wherein the modified FGF-21 polypeptide comprises a polypeptide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 3, wherein the polypeptide has a FGF-21 activity.

### Claim 89 (depends on 87, 88)

The method of claim 87 or 88, wherein the modified FGF-21 polypeptide is linked to a half-life extending moiety.

### Claim 90 (depends on 89)

The method of claim 89, wherein the modified FGF-21 polypeptide is linked to the half-life extending moiety via the side chain of a non-naturally encoded amino in the sequence of the FGF-21 polypeptide.

### Claim 91 (depends on 89, 90)

The method of claim 89 or 90, wherein the half-life extending moiety comprises albumin, an immunoglobulin constant region or a portion thereof, an immunoglobulin-binding polypeptide, an IgG, ABP, a PASylation moiety, a HESylation moiety, XTEN, an Fc region, and any combination thereof.

### Claim 92 (depends on 89, 90)

The method of claim 89 or 90, wherein the half-life extending moiety comprises a water soluble polymer.

### Claim 93 (depends on 92)

The method of claim 92, wherein the water soluble polymer is a PEG.

### Claim 94 (depends on 93)

The method of claim 93, wherein the PEG has an average molecular weight between about 10 kDa and about 40 kDa.

### Claim 95 (depends on 93, 94)

The method of claim 93 or 94, wherein the PEG has an average molecular weight of about 30 kDa.

### Claim 96 (depends on 90, 91, 92, 93, 94, 95)

The method of any one of claims 90 to 95, wherein the non-naturally encoded amino acid is a phenylalanine derivative.

### Claim 97 (depends on 96)

The method of claim 96, wherein the phenylalanine derivative is para-acetyl-L-phenylalanine.

### Claim 98 (depends on 96, 97)

The method of claim 96 or 97, wherein the half-life extending moiety is linked to the non-naturally encoded amino acid via an oxime linkage.

### Claim 99 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method of any one of claims 90 to 98, wherein the non-naturally encoded amino acid replaces amino acid Glutamine 109 of SEQ ID NO: 3.

### Claim 100 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 58 to 99, wherein the FGF-21 polypeptide is present at a concentration between about 1 mg/ml and about 40 mg/ml.

### Claim 101 (depends on 100)

The method of claim 100, wherein the FGF-21 polypeptide is present at a concentration of about 10 mg/ml or about 20 mg/ml.

### Claim 102 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 58 to 101, wherein the formulation is an aqueous formulation.

### Claim 103 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The method of any one of claims 58 to 102, wherein the FGF-21 polypeptide is PEG-FGF-21 (SEQ ID NO: 2).

### Claim 104

A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
(i) histidine at a concentration between about 10 mM and about 50 mM;
(ii) sucrose at a concentration between about 100 mM and about 1M;
(iii) Polysorbate 80 at a concentration between about 0.01% and about 0.1% (w/v); and,
(iv) DTPA at a concentration between about 10 μM and about 100 μM;
wherein the pH of the formulation is between about 6.7 and about 7.5.

### Claim 105

A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
(i) histidine at a concentration of about 20 mM;
(ii) sucrose at a concentration of about 600 mM;
(iii) Polysorbate 80 at a concentration of about 0.05% (w/v); and,
(iv) DTPA at a concentration of about 50 μM;
wherein the pH is about 7.1.

### Claim 106

A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
(i) histidine at a concentration of 20 mM;
(ii) sucrose at a concentration of 600 mM;
(iii) Polysorbate 80 at a concentration of 0.05% (w/v); and,
(iv) DTPA at a concentration of 50 □M;
wherein the pH is 7.1.

### Claim 107

A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
(i) histidine at a concentration of about 20 mM; and,
(ii) sucrose at a concentration of about 600 mM;
wherein the pH is about 7.0.

### Claim 108

A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
(i) histidine at a concentration of 20 mM; and,
(ii) sucrose at a concentration of 600 mM;
wherein the pH is 7.0.

### Claim 109

A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 10 mg/mL, comprising admixing
(i) histidine at a concentration of about 20 mM;
(ii) sucrose at a concentration of about 600 mM;
(iii) Polysorbate 80 at a concentration of about 0.05% (w/v); and,
(iv) DTPA at a concentration of about 50 μM;
wherein the pH is about 7.1.

### Claim 110

A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 20 mg/mL, comprising admixing
(i) histidine at a concentration of about 20 mM;
(ii) sucrose at a concentration of about 600 mM;
(iii) Polysorbate 80 at a concentration of about 0.05% (w/v); and,
(iv) DTPA at a concentration of about 50 μM;
wherein the pH is about 7.1.

### Claim 111

A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 10 mg/mL, comprising admixing
(i) histidine at a concentration of 20 mM;
(ii) sucrose at a concentration of 600 mM;
(iii) Polysorbate 80 at a concentration of 0.05% (w/v); and,
(iv) DTPA at a concentration of 50 μM;
wherein the pH is 7.1.

### Claim 112

A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 20 mg/mL, comprising admixing
(i) histidine at a concentration of 20 mM;
(ii) sucrose at a concentration of 600 mM;
(iii) Polysorbate 80 at a concentration of 0.05% (w/v); and,
(iv) DTPA at a concentration of 50 μM;
wherein the pH is 7.1.

### Claim 113 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

A pharmaceutical formulation prepared according to the method of any one of claims 58 to 112.

### Claim 114 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A kit comprising (i) the pharmaceutical formulation of any one of claim 1 to 57, or 113, and (ii) instructions for use.

### Claim 115 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of treating or preventing a disease or condition associated with fibrosis and/or diabetes in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical formulation of any one of claim 1 to 57, or 113.

### Claim 116 (depends on 115)

The method of claim 115, wherein the disease or condition is diabetes.

### Claim 117 (depends on 116)

The method of claim 116, wherein the diabetes is type 2 diabetes.

### Claim 118 (depends on 115)

The method of claim 115, wherein the disease or condition is nonalcoholic steatohepatitis (NASH).

### Claim 119 (depends on 115, 116, 117, 118)

The method of any one of claims 115 to 118, wherein administration of the effective amount of the pharmaceutical formulation to the subject decreases liver stiffness, decreases percentage body fat, decreases body weight, decreases liver-to-body weight ratio, decreases liver lipid content, decreases liver fibrosis area, decreases fasting blood glucose levels, decreases fasting triglyceride levels, decreases LDL cholesterol levels, decreases ApoB levels, decreases ApoC levels, increases HDL cholesterol, or any combination thereof.

### Claim 120 (depends on 115, 116, 117, 118, 119)

The method of any one of claims 115 to 119, wherein between about 1 mg and about 40 mg of FGF-21 polypeptide is administered per dose.

### Claim 121 (depends on 115, 116, 117, 118, 119, 120)

The method of any one of claims 115 to 120, wherein about 1 mg, about 5 mg, about 10 mg, about 20 mg, or about 40 mg of FGF-21 polypeptide is administered per dose.

### Claim 122 (depends on 115, 116, 117, 118, 119, 120, 121)

The method of any one claims 115 to 121, wherein the pharmaceutical formulation is administered subcutaneously.

### Claim 123 (depends on 122)

The method of claim 122, wherein the pharmaceutical formulation is administered subcutaneously using a safety syringe.

### Claim 124 (depends on 115, 116, 117, 118, 119, 120, 121, 122, 123)

The method of any one of claims 115 to 123, wherein the pharmaceutical formulation is administered daily or weekly.

### Claim 125 (depends on 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The method of any one of claims 115 to 124, wherein the administration of the pharmaceutical formulation to the subject results in
(i) reduction in levels of liver fat;
(ii) reduction in levels of liver injury;
(iii) reduction in levels of fibrosis;
(iv) decrease in levels of fibrosis biomarker serum Pro-C3 (N-terminal type III collagen propeptide);
(v) decrease in levels of alanine aminotransferase (ALT);
(vi) decrease in levels of aspartate aminotransferase (AST),
(vii) increase in levels of serum adiponectin;
(viii) decrease in levels of plasma LDL
(ix) increase in levels of plasma HDL;
(x) decrease in levels of plasma triglyceride;
(xi) reduction in level of liver stiffness; or
(xii) any combination thereof,
compared to the levels in untreated subjects or to the subject prior to the administration of the pharmaceutical formulation.

### Claim 126 (depends on 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The method of treatment of any one of claims 115 to 125, wherein the FGF-21 polypeptide is PEG-FGF-21 (SEQ ID NO: 2)

### Claim 127

A pharmaceutical formulation made by the process of admixing
(i) PEG-FGF-21 in amount to achieve a final concentration of about 10 mg/mL;
(ii) histidine in amount to achieve a final concentration of about 20 mM;
(iii) sucrose in amount to achieve a final a concentration of about 600 mM;
(iv) Polysorbate 80 in amount to achieve a final concentration of about 0.05% (w/v); and
(v) DTPA in amount to achieve a final concentration of about 50 μM; and
and adjust the pH at about 7.1.

### Claim 128

A pharmaceutical formulation made by the process of admixing
(i) PEG-FGF-21 in amount to achieve a final concentration of about 20 mg/mL;
(ii) histidine in amount to achieve a final concentration of about 20 mM;
(iii) sucrose in amount to achieve a final a concentration of about 600 mM;
(iv) Polysorbate 80 in amount to achieve a final concentration of about 0.05% (w/v); and
(v) DTPA in amount to achieve a final concentration of about 50 μM; and
and adjust the pH at about 7.1.

### Claim 129

A pharmaceutical formulation made by the process of admixing
(i) PEG-FGF-21 in amount to achieve a final concentration of 10 mg/mL;
(ii) histidine in amount to achieve a final concentration of 20 mM;
(iii) sucrose in amount to achieve a final a concentration of 600 mM;
(iv) Polysorbate 80 in amount to achieve a final concentration of 0.05% (w/v); and
(v) DTPA in amount to achieve a final concentration of 50 μM; and
and adjust the pH at 7.1.

### Claim 130

A pharmaceutical formulation made by the process of admixing
(i) PEG-FGF-21 in amount to achieve a final concentration of 20 mg/mL;
(ii) histidine in amount to achieve a final concentration of 20 mM;
(iii) sucrose in amount to achieve a final a concentration of 600 mM;
(iv) Polysorbate 80 in amount to achieve a final concentration of 0.05% (w/v); and
(v) DTPA in amount to achieve a final concentration of 50 μM; and
and adjust the pH at 7.1.
